Codexis, Inc. (CDXS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Codexis, Inc. is an enzyme engineering company leveraging its proprietary CodeEvolver® directed evolution technology platform. Following a strategic restructuring in late 2023, the company discontinued investment in its biotherapeutics business and now operates as a single reportable segment focused on pharmaceutical manufacturing and its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenues | $7,979 | $21,323 | $25,052 | $34,305 |
| Net Loss | $(22,755) | $(11,523) | $(34,260) | $(34,140) |
| Net Loss Per Share | $(0.32) | $(0.17) | $(0.49) | $(0.51) |
| Product Gross Margin | 45% | 71% | 47% | 60% |
| Cash & Equivalents | $18,595 | $65,116 | $18,595 | $65,116 |
| Short-term Investments | $54,604 | $0 | $54,604 | $0 |
| Long-term Debt | $28,365 | $0 | $28,365 | $0 |
| Working Capital | $60,859 | $57,636 | $60,859 | $57,636 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 63% year-over-year in Q2 2024. Product revenue fell 43% and R&D revenue fell 83%. The decline is attributed to lower sales of branded pharmaceutical products and the absence of significant non-cash revenue recognized in Q2 2023 related to Pfizer license agreements.
- Increased Net Loss: Q2 net loss widened to $22.8 million from $11.5 million in the prior year, driven primarily by the revenue contraction. However, operating expenses decreased 10% year-over-year due to headcount reductions and lower facility costs.
- Debt Financing: In February 2024, the company entered into a $40 million term loan with Innovatus Life Sciences. The first tranche of $30 million was funded, resulting in long-term debt of $28.4 million (net of discounts/costs) on the balance sheet. This increased interest expense significantly compared to the prior year.
- Liquidity Shift: Cash and cash equivalents decreased from $65.1 million to $18.6 million, while short-term investments increased to $54.6 million. Total liquid assets (cash + investments) remain at $73.2 million.
Guidance, Outlook, and Risks
- Strategic Focus: Management is prioritizing the pharmaceutical manufacturing business and the development of the ECO Synthesis™ platform for RNA-based therapeutics. Pre-commercial customer testing for ECO Synthesis is expected in 2024, with early commercial licenses anticipated in 2025.
- Asset Monetization: The company has divested several biotherapeutics assets (Fabry, Pompe, homocystinuria, etc.) to third parties, retaining rights to future milestone and royalty payments.
- Capital Resources: Management believes existing cash, investments, and the Innovatus loan facility are sufficient to fund operations for at least the next 12 months. A new $75 million "at-the-market" equity sales agreement with Cantor Fitzgerald was established in May 2024, though no sales have occurred yet.
- Risks: Key risks include dependence on a limited number of customers (top customers accounted for 40% of YTD revenue), reliance on third-party contract manufacturers, and the need to achieve profitability. The company is subject to financial covenants under the Innovatus loan, including liquidity and net product revenue thresholds.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the Innovatus Loan covenants, specifically the liquidity and net product revenue thresholds effective September 30, 2024.
- Customer Concentration: Assess the stability of revenue from top customers, which represented 40% of total revenue in the first half of 2024.
- ECO Synthesis Progress: Monitor the timeline for pre-commercial customer testing and the transition to commercial licensing for the ECO Synthesis™ platform.
- Cash Burn Rate: Review the net cash used in operating activities ($20.0 million for YTD 2024) against current liquid assets to validate the 12-month runway estimate.
- Asset Divestitures: Track the realization of milestone payments from recent biotherapeutics asset sales to Crosswalk Therapeutics and other private companies.